HRP20211129T1 - Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a - Google Patents
Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a Download PDFInfo
- Publication number
- HRP20211129T1 HRP20211129T1 HRP20211129TT HRP20211129T HRP20211129T1 HR P20211129 T1 HRP20211129 T1 HR P20211129T1 HR P20211129T T HRP20211129T T HR P20211129TT HR P20211129 T HRP20211129 T HR P20211129T HR P20211129 T1 HRP20211129 T1 HR P20211129T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- cancer
- adenocarcinoma
- acid sequence
- pharmaceutical composition
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims 3
- XBSNXOHQOTUENA-KRAHZTDDSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO XBSNXOHQOTUENA-KRAHZTDDSA-N 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000006587 bladder adenocarcinoma Diseases 0.000 claims 1
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
1. Izolirano antitijelo koje se veže za Sialyl-Lewisa i inducira ADCC ili CDC aktivnost, pri čemu navedeno antitijelo sadrži varijabilnu domenu teškog lanca (VH) i varijabilnu domenu lakog lanca (VL), gdje navedena VH domena i navedena VL domena, redom, sadrže amino kiselinsku sekvencu ostataka 20-142 iz SEQ ID NO: 2 i ostataka 20-130 iz SEQ ID NO: 4.
2. Izolirani polinukleotid koji kodira teški lanac antitijela, pri čemu navedeni teški lanac antitijela sadrži varijabilnu domenu teškog lanca (VH) koja ima amino kiselinsku sekvencu ostataka 20-142 iz SEQ ID NO: 2; i izolirani polinukleotid koji kodira laki lanac antitijela, pri čemu navedeni laki lanac antitijela sadrži varijabilnu domenu lakog lanca (VL) koja ima amino kiselinsku sekvencu ostataka 20-130 iz SEQ ID NO: 4, naznačen time što se antitijelo koje sadrži navedeni teški lanac antitijela i navedeni laki lanac antitijela veže za Sialyl-Lewisa i inducira ADCC ili CDC aktivnost.
3. Izolirani polinukleotid prema patentnom zahtjevu 2, naznačen time što je navedena amino kiselinska sekvenca VH domena kodirana sekvencom nukleinske kiseline ostataka 58-426 iz SEQ ID NO: 1.
4. Izolirani polinukleotid prema patentnom zahtjevu 2, naznačen time što je navedena amino kiselinska sekvenca VL domene kodirana sekvencom nukleinske kiseline ostataka 58-390 iz SEQ ID NO: 3.
5. Izolirano antitijelo prema patentnom zahtjevu 1, naznačeno time što je navedeno antitijelo humano antitijelo, poželjno IgG ili IgM izotipa, pri čemu navedeno IgG antitijelo poželjno pripada IgG 1 potklasi.
6. Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 5 i farmaceutski prihvatljiv nosač.
7. Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 5 i farmaceutski prihvatljiv nosač, za uporabu u liječenju ili prevenciji bolesti, koja uporaba obuhvaća primjenu terapeutski efikasne količine navedene farmaceutske kompozicije kod subjekta kome je to potrebno.
8. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 7, naznačena time što navedena bolest predstavlja oblikovanje karcinoma ili tumora, pri čemu stanice navedenog karcinoma ili navedenog tumora eksprimiraju sLea; ili gdje su navedeni karcinom ili tumor odabrani iz grupe koja se sastoji od tumora gastrointestinalnog trakta, karcinoma debelog crijeva, kolorektalnog adenokarcinoma, metastatskog karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma pankreasa, adenokarcinoma pankreasa, sitnostaničnog karcinoma pluća, adenokarcinoma mjehura, karcinoma jajnika pečatnog prstena, karcinoma jajnika, metastatskog karcinoma, adenokarcinoma želuca, adenokarcinoma jednjaka, adenokarcinoma grla, adenokarcinoma urogenitalnog trakta, i adenokarcinoma dojke.
9. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 7, naznačena time što je navedena farmaceutska kompozicija prilagođena za istovremenu ili sukcesivnu primjenu drugog terapeutskog sredstva, poželjno, navedeno drugo terapeutsko sredstvo je kemoterapijsko sredstvo ili imunoterapijsko sredstvo.
10. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 9, naznačena time što je drugo terapeutsko sredstvo taksol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361870137P | 2013-08-26 | 2013-08-26 | |
PCT/US2014/052631 WO2015053871A2 (en) | 2013-08-26 | 2014-08-26 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa |
EP14852746.8A EP3041507B1 (en) | 2013-08-26 | 2014-08-26 | Nucleic acids encoding human antibodies to sialyl-lewis a |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211129T1 true HRP20211129T1 (hr) | 2021-10-15 |
Family
ID=52480556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211129TT HRP20211129T1 (hr) | 2013-08-26 | 2021-07-14 | Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a |
Country Status (22)
Country | Link |
---|---|
US (4) | US9475874B2 (hr) |
EP (2) | EP3041507B1 (hr) |
JP (6) | JP6626445B2 (hr) |
KR (4) | KR20160054501A (hr) |
CN (2) | CN105764526B (hr) |
AU (3) | AU2014332442B2 (hr) |
CA (2) | CA2922478C (hr) |
CY (1) | CY1124435T1 (hr) |
DK (1) | DK3041507T3 (hr) |
ES (1) | ES2880709T3 (hr) |
HK (1) | HK1226295A1 (hr) |
HR (1) | HRP20211129T1 (hr) |
HU (1) | HUE056325T2 (hr) |
IL (2) | IL244297B (hr) |
LT (1) | LT3041507T (hr) |
PL (1) | PL3041507T3 (hr) |
PT (1) | PT3041507T (hr) |
RS (1) | RS62189B1 (hr) |
RU (1) | RU2699289C2 (hr) |
SI (1) | SI3041507T1 (hr) |
WO (1) | WO2015053871A2 (hr) |
ZA (1) | ZA201601354B (hr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105764526B (zh) * | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
GB201515094D0 (en) * | 2015-08-25 | 2015-10-07 | Univ Nottingham | Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto |
BR112019000098A2 (pt) * | 2016-07-14 | 2019-04-09 | Bioarctic Ab | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio |
BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
CA3045466A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
MA46814B2 (fr) | 2017-02-10 | 2022-09-30 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
JP7264831B2 (ja) * | 2017-06-15 | 2023-04-25 | ディベロップメント センター フォー バイオテクノロジー | 抗globo h抗体を含有する抗体-薬物コンジュゲートおよびその使用 |
TWI795415B (zh) * | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
WO2019023148A1 (en) | 2017-07-24 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
PT110526B (pt) | 2018-01-26 | 2021-02-04 | Univ Nova De Lisboa | Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais |
KR102115236B1 (ko) * | 2018-01-29 | 2020-05-27 | (주)에스엠티바이오 | 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체 |
US20220049011A1 (en) * | 2018-09-10 | 2022-02-17 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
JP7374544B2 (ja) | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物 |
EP3867279A4 (en) * | 2018-10-19 | 2022-07-13 | Memorial Sloan Kettering Cancer Center | CHIMERA ANTIGEN RECEPTORS TARGETING SIALYL LEWIS A AND THEIR USES |
WO2021105988A1 (en) * | 2019-11-26 | 2021-06-03 | Ramot At Tel-Aviv University Ltd. | Antibodies to carbohydrate antigens |
CN114605550B (zh) * | 2020-12-08 | 2023-09-22 | 东莞市朋志生物科技有限公司 | 抗ca19-9的抗体、其应用和检测ca19-9的试剂盒 |
WO2022153298A1 (en) * | 2021-01-12 | 2022-07-21 | Yeda Research And Development Co. Ltd. | Antibodies to cancer glycosylation and uses thereof |
AU2022244125A1 (en) | 2021-03-26 | 2023-10-19 | BioNTech SE | Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA128362A (en) | 1910-07-25 | 1910-09-27 | Victor Herbert Gregory | Furnace for drawing glass |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2074825C (en) | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6271242B1 (en) | 1992-02-10 | 2001-08-07 | Bristol-Myers Squibb Co. | Method for treating cancer using a tyrosine protein kinase inhibitor |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH0630786A (ja) * | 1992-07-14 | 1994-02-08 | Kyowa Hakko Kogyo Co Ltd | バイスペシフィック抗体 |
US5728868A (en) | 1993-07-15 | 1998-03-17 | Cancer Research Campaign Technology Limited | Prodrugs of protein tyrosine kinase inhibitors |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5925376C1 (en) | 1994-01-10 | 2001-03-20 | Madalene C Y Heng | Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds |
DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5911995A (en) | 1994-08-19 | 1999-06-15 | Regents Of The University Of Minnesota | EGF-genistein conjugates for the treatment of cancer |
US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
DK0805628T3 (da) | 1995-01-17 | 2003-07-14 | Brigham & Womens Hospital | Receptor specifik transepitheltransport af immunogener |
GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US6127366A (en) | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU711142B2 (en) | 1995-12-08 | 1999-10-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US5958769A (en) | 1996-01-18 | 1999-09-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
JP2000504017A (ja) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
JP2000504014A (ja) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6254868B1 (en) | 1996-03-20 | 2001-07-03 | Immunomedics, Inc. | Glycosylated humanized B-cell specific antibodies |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
US5648239A (en) | 1996-06-21 | 1997-07-15 | Incyte Pharmaceuticals, Inc. | Human camp-dependent protein kinase inhibitor homolog |
CA2259222A1 (en) | 1996-06-27 | 1997-12-31 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
ATE359822T1 (de) | 1996-08-12 | 2007-05-15 | Mitsubishi Pharma Corp | Medikamente enthaltend rho-kinase inhibitoren |
US6040305A (en) | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6030982A (en) | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
US5945429A (en) | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6013662A (en) | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6093737A (en) | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998032741A1 (en) | 1997-01-29 | 1998-07-30 | Zeneca Limited | Inhibitors of farnesyl protein transferase |
ZA981080B (en) | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
CA2280794A1 (en) | 1997-02-20 | 1998-08-27 | The Regents Of The University Of California | Plasmon resonant particles, methods and apparatus |
AU6542898A (en) * | 1997-03-05 | 1998-09-22 | John Wayne Cancer Institute | Sialyl lewis antigens as targets for immunotherapy |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
US6225322B1 (en) | 1997-06-17 | 2001-05-01 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6051582A (en) | 1997-06-17 | 2000-04-18 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6239140B1 (en) | 1997-06-17 | 2001-05-29 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6159984A (en) | 1997-06-17 | 2000-12-12 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
NZ502646A (en) | 1997-08-15 | 2002-04-26 | Cephalon Inc | A synergistic combination of tyrosine kinase inhibitors and chemical castration agents |
US6103723A (en) | 1997-10-17 | 2000-08-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ATE205195T1 (de) | 1997-10-22 | 2001-09-15 | Astrazeneca Ab | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren |
WO1999020612A1 (en) | 1997-10-22 | 1999-04-29 | Astrazeneca Uk Limited | Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
US6124465A (en) | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
AU731272B2 (en) | 1997-11-28 | 2001-03-29 | Lg Chemical Ltd. | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
US6054466A (en) | 1997-12-04 | 2000-04-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
US6335156B1 (en) | 1997-12-18 | 2002-01-01 | The Johns Hopkins University School Of Medicine | 14-3-3σ arrests the cell cycle |
US6436960B1 (en) | 1998-02-02 | 2002-08-20 | Lg Chemical Ltd. | Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof |
ATE259826T1 (de) | 1998-04-27 | 2004-03-15 | Warner Lambert Co | Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase |
PT1094815E (pt) | 1998-07-06 | 2004-04-30 | Janssen Pharmaceutica Nv | Inibidores da proteina farnesil transferase para tratamento de artropatias |
US6034053A (en) | 1998-07-13 | 2000-03-07 | Wayne Hughes Institute | EGF-isoflavone conjugates for the prevention of restenosis |
US6787638B1 (en) | 1998-12-02 | 2004-09-07 | Applied Molecular Evolution, Inc. | Tumor specific human monoclonal antibodies and methods of use |
US6362188B1 (en) | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6372747B1 (en) | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
FR2787327B1 (fr) | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
US6432959B1 (en) | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
ES2206191T3 (es) | 1999-01-11 | 2004-05-16 | Princeton University | Inhibidores de alta afinidad para validacion de dianas y usos de los mismos. |
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6143766A (en) | 1999-04-16 | 2000-11-07 | Warner-Lambert Company | Benzopyranone and quinolone inhibitors of ras farnesyl transferase |
US6458935B1 (en) | 1999-06-23 | 2002-10-01 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US6403581B1 (en) | 2000-01-19 | 2002-06-11 | American Cyanamid Company | Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives |
EP1490494A1 (en) | 2002-04-01 | 2004-12-29 | Walter Reed Army Institute of Research | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
JP5250850B2 (ja) | 2006-06-29 | 2013-07-31 | ディーエスエム アイピー アセッツ ビー.ブイ. | 改善されたポリペプチド発現を達成する方法 |
JP5382692B2 (ja) | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
CA2698374C (en) | 2007-09-07 | 2018-04-03 | Children's Hospital Medical Center | Use of secretor, lewis and sialyl antigen levels as predictors for disease |
RU2523419C2 (ru) | 2008-07-15 | 2014-07-20 | Дженетек, Инк. | Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений |
CN102264763B (zh) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
US20110311517A1 (en) * | 2009-02-10 | 2011-12-22 | Shenogen Pharma Group, Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
MX349662B (es) * | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
US20150023954A1 (en) * | 2012-03-23 | 2015-01-22 | Memorial Sloan-Kettering Cancer Center | Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
KR20160002713A (ko) * | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
CN105764526B (zh) * | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
WO2019073069A1 (en) * | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN) |
EP3867279A4 (en) * | 2018-10-19 | 2022-07-13 | Memorial Sloan Kettering Cancer Center | CHIMERA ANTIGEN RECEPTORS TARGETING SIALYL LEWIS A AND THEIR USES |
-
2014
- 2014-08-26 CN CN201480057851.8A patent/CN105764526B/zh active Active
- 2014-08-26 RU RU2016111015A patent/RU2699289C2/ru active
- 2014-08-26 WO PCT/US2014/052631 patent/WO2015053871A2/en active Application Filing
- 2014-08-26 KR KR1020167007644A patent/KR20160054501A/ko active Application Filing
- 2014-08-26 HU HUE14852746A patent/HUE056325T2/hu unknown
- 2014-08-26 LT LTEPPCT/US2014/052631T patent/LT3041507T/lt unknown
- 2014-08-26 ES ES14852746T patent/ES2880709T3/es active Active
- 2014-08-26 PT PT148527468T patent/PT3041507T/pt unknown
- 2014-08-26 RS RS20210929A patent/RS62189B1/sr unknown
- 2014-08-26 KR KR1020207019821A patent/KR102313341B1/ko active IP Right Grant
- 2014-08-26 AU AU2014332442A patent/AU2014332442B2/en active Active
- 2014-08-26 PL PL14852746T patent/PL3041507T3/pl unknown
- 2014-08-26 DK DK14852746.8T patent/DK3041507T3/da active
- 2014-08-26 EP EP14852746.8A patent/EP3041507B1/en active Active
- 2014-08-26 EP EP21181759.8A patent/EP3906945A3/en active Pending
- 2014-08-26 KR KR1020217019368A patent/KR102362630B1/ko active IP Right Grant
- 2014-08-26 JP JP2016539019A patent/JP6626445B2/ja active Active
- 2014-08-26 CA CA2922478A patent/CA2922478C/en active Active
- 2014-08-26 SI SI201431854T patent/SI3041507T1/sl unknown
- 2014-08-26 CA CA3090644A patent/CA3090644C/en active Active
- 2014-08-26 US US14/468,827 patent/US9475874B2/en active Active
- 2014-08-26 KR KR1020227004406A patent/KR102553717B1/ko active IP Right Grant
- 2014-08-26 CN CN202011316903.2A patent/CN112695039A/zh active Pending
-
2016
- 2016-02-25 IL IL244297A patent/IL244297B/en active IP Right Grant
- 2016-02-26 ZA ZA2016/01354A patent/ZA201601354B/en unknown
- 2016-09-23 US US15/275,174 patent/US20170015756A1/en not_active Abandoned
- 2016-12-16 HK HK16114384A patent/HK1226295A1/zh unknown
-
2018
- 2018-12-27 JP JP2018244315A patent/JP7161397B2/ja active Active
-
2020
- 2020-02-11 US US16/788,251 patent/US20200247900A1/en not_active Abandoned
- 2020-02-20 AU AU2020201225A patent/AU2020201225B2/en active Active
- 2020-08-19 IL IL276819A patent/IL276819A/en unknown
-
2021
- 2021-06-22 JP JP2021103311A patent/JP2021151263A/ja active Pending
- 2021-07-14 HR HRP20211129TT patent/HRP20211129T1/hr unknown
- 2021-07-21 CY CY20211100653T patent/CY1124435T1/el unknown
-
2022
- 2022-07-26 AU AU2022209226A patent/AU2022209226A1/en active Pending
- 2022-12-28 JP JP2022211698A patent/JP7299405B2/ja active Active
-
2023
- 2023-04-14 US US18/134,844 patent/US20230365707A1/en active Pending
- 2023-09-25 JP JP2023160194A patent/JP2023165831A/ja active Pending
-
2024
- 2024-02-20 JP JP2024023605A patent/JP2024050966A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211129T1 (hr) | Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a | |
RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
HRP20201939T1 (hr) | Anti-c10orf54 antitijela i njihova primjena | |
RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
JP2018504105A5 (hr) | ||
HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
HRP20201404T1 (hr) | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita | |
RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
HRP20160190T1 (hr) | Protutijela anti-igf | |
JP2017149720A5 (hr) | ||
RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
JP2016534735A5 (hr) | ||
HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
JP2014158469A5 (hr) | ||
RU2016114074A (ru) | Анти-rspo антитела и способы применения | |
HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen | |
RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
RU2013152164A (ru) | Анти-в7-н3-антитело | |
JP2014205674A5 (hr) | ||
JP2018515137A5 (hr) |